• On 27 June 2026, Adaptive Biotechnologies Corporation was removed from several Russell indices, including the Russell 3000E, Russell 3000E Growth Benchmark, Russell Microcap Index and Russell Microcap Growth Benchmark Index.
• This broad index removal can alter how index-linked and institutional investors hold or trade Adaptive Biotechnologies, potentially reshaping the stock’s investor base and liquidity profile.
• We’ll now examine how Adaptive Biotechnologies’ removal from multiple Russell indices may influence its existing investment narrative and future risk profile.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Adaptive Biotechnologies Investment Narrative Recap

To own Adaptive Biotechnologies, you need to believe its MRD platform can justify ongoing losses while Immune Medicine either matures or is successfully separated. The broad Russell index removals do not directly change these core fundamentals in the near term, but they can add some short term trading volatility and may compound the key risk that continued unprofitability could eventually force less favorable funding or deeper cost cuts.

The most relevant recent development is Adaptive’s June 2026 decision to explore separating its MRD and Immune Medicine businesses. That review, alongside raised 2026 MRD revenue guidance to US$260 million to US$270 million, sits at the heart of the current catalyst: MRD’s path toward scale and improved cash burn versus the risk that Immune Medicine’s uncertain economics and any future transaction terms could weigh on shareholder outcomes.

Yet beneath the index changes, one risk investors should be watching closely is whether ongoing losses and cash needs could eventually force...

Adaptive Biotechnologies' narrative projects $451.6 million revenue and $70.4 million earnings by 2029. This requires 15.2% yearly revenue growth and an earnings increase of about $120 million from -$49.7 million today.

Uncover how Adaptive Biotechnologies' forecasts yield a $20.14 fair value, a 6% downside to its current price.

Exploring Other Perspectives

While consensus highlights funding risk and partner dependence, the most optimistic analysts were assuming revenue could reach about US$474 million by 2029, so this broad index removal could prompt some of those views to be revisited as opinions adjust around how quickly Adaptive can really grow into that profile.

Explore 3 other fair value estimates on Adaptive Biotechnologies - why the stock might be worth 6% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Adaptive Biotechnologies research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Adaptive Biotechnologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Adaptive Biotechnologies' overall financial health at a glance.

Ready For A Different Approach?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Explore 27 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find 41 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.